BioNTech buys Biotheus and its Keytruda rival for $950m
BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid tumours." It is paying $800 million to acquire all of Biotheus' issued share capital and up to $150 million in potential milestone payments.
BioNTech to buy Biotheus, gaining control of cancer bispecific
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit Therapeutics’ ivonescimab.
BioNTech strikes $950mn deal for Chinese drugmaker Biotheus
BioNTech has acquired Chinese cancer drugmaker Biotheus in a near $1bn deal, as the Covid-19 vaccine maker taps into the country’s health sciences expertise to develop promising immunotherapy drugs. The deal gives the German biotech control of a drug class that has shown potential to outperform Merck’s blockbuster cancer treatment Keytruda,
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on Wednesday.
BioNTech acquires its Chinese cancer drug partner
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two companies were already co-developing an experimental antibody that targets two proteins found on cancer cells.
Germany's BioNTech to buy Chinese firm with promising cancer drug
Germany pharmaceutical company BioNTech, which shot to global prominence after its early coronavirus vaccine, has boosted its cancer drug development by agreeing to buy Chinese firm Biotheus. The Mainz-based group said in a statement on Wednesday it will pay up to $950 million,
Cambridge Network21m
Keytruda LoE: A seismic shift for oncology?
Within the PD-(L)1 class, Keytruda is responsible for over 55% of the total global sales. Its current revenue total makes ...
FierceBiotech1d
BioNTech pays $800M to take control of potential Keytruda killer
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
MM&M13h
BioNTech spends $800M upfront to pick up China-based Biotheus
Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...
The Pharma Letter2d
Merck's Keytruda and Citius' Lymphir combo trial shows promising results
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
Cure Today6d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
BioSpace10dOpinion
Opinion: Ten Years After Keytruda’s Seminal Approval, Immuno-oncology Is Poised for the Next Revolution
While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...
Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
Cure Today1d
Jemperli-Chemo Regimen Shows Survival Promise in Advanced NSCLC
Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS ...
Is MRK Stock Undervalued At $100?
Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.
Healthline9d
All About Keytruda
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time).
Business Insider2d
Medicenna announces single-agent activity of MDNA11 from dose expansion cohort
The Safety Review Committee approved enrollment of the next higher-dose cohorts as follows: Cohort 3: 120 microgram/kg Q2W MDNA11 and 400 mg Q6W KEYTRUDA; Cohort 4: 120 microgram/kg Q3W MDNA11 and ...